# Window of Opportunity Study in Colorectal Cancer

> **NCT03984578** · PHASE2 · COMPLETED · sponsor: **National Cancer Centre, Singapore** · enrollment: 33 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** CAPEOX
- **DRUG:** Pembrolizumab
- **DRUG:** Capecitabine/ 5-FU
- **DRUG:** Pembrolizumab
- **DRUG:** CAPEOX/Pembrolizumab
- **DRUG:** Pembrolizumab alone
- **PROCEDURE:** Surgical resection

## Key facts

- **NCT ID:** NCT03984578
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-12
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03984578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03984578, "Window of Opportunity Study in Colorectal Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03984578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*